<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920242</url>
  </required_header>
  <id_info>
    <org_study_id>1526 RIF_2</org_study_id>
    <nct_id>NCT02920242</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare safety and efficacy of a generic rifaximin tablet to the reference
      listed drug in the treatment of travelers' diarrhea. Additionally both the generic and
      reference formulations will be tested for superiority against a placebo tablet.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>study day 5</time_frame>
    <description>Clinical cure is defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Last Unformed Stool</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical failure</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement of diarrheal syndrome</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unformed stools</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or absence and severity of signs and symptoms of enteric infection</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure rate</measure>
    <time_frame>study day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>study day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xifaxan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 1 Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 1 placebo tablet 3 times per day for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin (Sandoz GmbH) tablet</intervention_name>
    <description>200 mg tablet administered orally.</description>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin (Xifaxan)</intervention_name>
    <description>200 mg tablet administered orally</description>
    <arm_group_label>Xifaxan</arm_group_label>
    <other_name>Xifaxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo tablet administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is able to read and understood the language of the Informed Consent Form and
             Patient Information.

          -  International travelers with a duration of stay in host country long enough to attend
             schedules visits.

          -  Affected by naturally acquired acute diarrhea, defined as the passage of at least 3
             unformed stools within 24 hours immediately preceding randomization preceding
             randomization

        Exclusion Criteria:

          -  Hypersensitivity to rifaximin or any of the rifamycin antimicrobial agents or to any
             of the excipients of the study drug.

          -  Pregnant, breast feeding or planning pregnancy

          -  Acute diarrhea for &gt; 72 hours immediately prior to randomization.

          -  Presence of fever (≥ 100 °F/37.8°C) or hematochezia (blood in stool, noted visually)
             or clinical findings suggesting moderate or severe dehydration.

        Other protocol inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandoz</last_name>
    <email>info.lek@sandoz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandoz</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>September 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Travelers</keyword>
  <keyword>diarrhea</keyword>
  <keyword>rifaximin</keyword>
  <keyword>equivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
